Related Experiment Video
Updated: Jun 8, 2026
08:56
Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
Published on: July 12, 2022
Therapy-induced senescence in cancer
Jonathan A Ewald1, Joshua A Desotelle, George Wilding
1Department of Urology, University of Wisconsin, School of Medicine and Public Health, 1111 Highland Ave, Madison, WI 53705-2275, USA.
Journal of the National Cancer Institute
|September 23, 2010
Summary
Therapy-induced senescence (TIS) offers a promising cancer treatment strategy by causing cancer cells to stop dividing. This approach may reduce side effects and enhance anti-tumor immunity, though more research is needed.
Area of Science:
- Oncology
- Cell Biology
- Immunology
Background:
- Cellular senescence is a stable cell cycle arrest triggered by stress, characterized by specific molecular and morphological changes.
- Senescence markers are detectable in tumors, and senescence can be induced in cancer cells lacking key tumor suppressors like p53 and retinoblastoma protein.
Purpose of the Study:
- To review the current understanding of therapy-induced senescence (TIS) as a cancer treatment strategy.
- To highlight the mechanisms, agents, and biomarkers associated with TIS.
- To identify challenges and encourage further development of TIS in clinical oncology.
Main Methods:
- Review of existing literature on cellular senescence and TIS.
- Analysis of TIS induction by anticancer compounds and radiation.
- Examination of TIS-related mechanisms, agents, and biomarkers.
Main Results:
- TIS can be induced in cancer cells, potentially leading to reduced toxicity and enhanced anti-tumor immune responses.
- Current research indicates TIS as a novel functional target for improving cancer therapy outcomes.
- Challenges remain, including the need for more effective senescence-inducing agents and comprehensive data on tumor response.
Conclusions:
- Therapy-induced senescence (TIS) presents a promising avenue for cancer treatment with potential for reduced side effects and improved immune engagement.
- Further research into novel senescence-inducing compounds and targeted approaches is crucial for advancing TIS in clinical practice.
- Overcoming current hurdles will facilitate the broader application of TIS in cancer therapy.
Related Concept Videos
02:15Replicative Cell Senescence
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
02:15Replicative Cell Senescence
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:12Loss of Tumor Suppressor Gene Functions
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...